Health Care Professionals Forum. May 19, 2016

Similar documents
Recent trends in medical cannabis use in Canada

Understanding the New Access to Cannabis for Medical Purposes Regulations

Are We All Going to Pot?: Legal Issues Arising from Cannabis-Industry Growth The Canadian Perspective

Municipal Implications of Impending Marijuana Legalization

Trends in medical cannabis use in Canada,

Corporate Development Committee Report

James Donaldson CEO and Executive Director

Legalization and Regulation of Recreational Cannabis PRESENTATION LPPANS NOVEMBER 22, 2017

Model. Medical Access to Marihuana first established on a case by case basis using exemptions

Research: Medical Cannabis

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis

Cannabis Regulation in Canada:

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis. February 2018

Legalization of Cannabis: The Way Forward

Legalization of non-medical Cannabis OPSBA Update September 08, 2017

Canopy Growth Corporation

Cannabis Legalization August 22, Ministry of Attorney General Ministry of Finance

Agracan - LP. Palmerston Industrial Park Cannabis Cultivation Facility

Torkin Manes LegalPoint

Cannabis Legalization: Implications, Considerations, and Proposed Actions for the CSRD. Development Services

Copyright Canadian Nurses Association 50 Driveway Ottawa, Ont. K2P 1E2 CANADA

Marijuana and the Workplace : Changing Times

Yukon s Proposed Framework for. Legalized Cannabis 30 GRAMS MINIMUM AGE

The federal legislation, Cannabis Act that legalizes recreational cannabis comes into effect on October 17, 2018.

Legalizing Marijuana: Anticipated Challenges

Proposed Excise Duty Framework for Cannabis Products

Use of Cannabinoids in Medical Practice

SUBJECT: Cannabis legislation and implications for the City of Burlington

Review of Controlled Drugs and Substances Act

Processing of Medical Marihuana Products in the Light Industrial Business Park Zone

Ryan Smith, Community Planning Department Manager

Medical Marijuana and the Workplace: Human Rights Considerations for ONA Members

MODIFICATION OF APPLICATION TO BECOME A LICENSED PRODUCER UNDER THE ACCESS TO CANNABIS FOR MEDICAL PURPOSES REGULATIONS

CANNABIS IN YOUR COMMUNITY. A Presentation to CPAA Conference May 2017

City of Toronto Recommendations for Cannabis Legalization

Ryan Smith, Community Planning Department Manager. Zoning Bylaw Text Amendment for Cannabis Production and Retail Cannabis Sales

Regula'on of Medical Cannabis in Canada: Reflec'on on the Present and Future

A COMMITTEE OF THE WHOLE MEETING WILL BE HELD IN THE MUNICIPAL COUNCIL CHAMBERS AT CITY HALL ON THURSDAY, NOVEMBER 16, 2017 AT 12:00 P.M.

Explanatory note for Operational Policy Manual (OPM) # , Cannabis for Medical Purposes

Legalization, Regulation and Restriction of Access to Cannabis

Cannabis and What we Know. Bonnie Schnittker RN PHN Public Health Nurse October 20, 2017

POLICY NUMBER: POL 153

Response to request for submissions regarding regulation of non-medical cannabis

Cannabis Legalization

Faculty/Presenter Disclosure

Cannabis Law. June 29, 2018

420 ADVISORY MANAGEMENT

CMA Response: Health Canada s Medical Marihuana Regulatory Proposal. Submitted to the Office of Controlled Substances Health Canada.

Cannabis as Therapy for People Living with HIV/AIDS:

Colin Fetter Partner, Edmonton Office Direct: Presented by:

INVESTOR DECK. February 2017

Canadian Marijuana Industry Snapshot: 17 Charts

January 19, Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9

Consumer Information Cannabis (Marihuana, marijuana)

Medical (and Recreational) Marijuana in the Workplace. Jamie LeMesurier, QC Chad Sullivan

SUBSTANCE USE GUIDELINES

LEGALIZED AND MEDICAL MARIJUANA IN THE WORKPLACE

ADMINISTRATIVE REPORT

Important Information

Ontario Government to Grow LCBO: Recreational Cannabis to be sold at Government Stores

Canada s green rush and the end of prohibition. Sara Zborovski Michael Posnikoff Marino Sveinson

Medical Cannabis. Danial Schecter, MD, CCFP. Vocational Rehabilitation Association November 7th, Executive Director Cannabinoid Medical Clinic

Responsible Retailing of Recreational Cannabis. Recommendations to British Columbia s Cannabis Regulation Engagement Secretariat

Background. Recommendation 1

Canadian National Medical Marijuana Association (CNMMA)

B.C. Cannabis PRIVATE RETAIL LICENSING GUIDE Applications and Operations

RECREATIONAL CANNABIS. Province of British Columbia regulations

Cannabis Legalization and Regulation in British Columbia Discussion Paper

CANNABIS IN CANADA. Prepared by: Shaun Casey, CEO Richard Hong, VP Sales OUR VIEWS ON BILL C-45 - TO THE STANDING COMMITTEE ON HEALTH

Written Brief to the Standing Committee on Health

REQUEST FOR DECISION Subject: Bylaw 420 Land Use Bylaw Amending Bylaw Cannabis and Cannabis Related Businesses Definitions

Medicinal Cannabis. Patient Log Book. Record your cannabis use and find the right dose

Prince Edward Island: Preparation for Cannabis Legalization

Cannabis and the Workplace. By Karen Stokke Learning Manager. Stereotypes. Things are changing

The Cannabis model in Canada and the USA. Dr Mark A Ware MD MRCP MSc McGill University Montreal, Quebec, Canada

Cannabis Legalization

REQUEST FOR DECISION Subject: Bylaw 420 Land Use Bylaw Amending Bylaw Cannabis and Cannabis Related Business Definitions

Provincially-Licensed Cannabis Retail Stores in Toronto

British Columbia Pharmacy Association

ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL

Nevada s Marijuana Roots

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

Cannabis use carries significant health risks, especially for people who use it frequently and or/begin to use it at an early age.

Cannabis Regulations Response and Update on Cannabis Legalization

Legalization and Regulation of Cannabis Enforcement Challenges

Cannabis for Medical Purposes

Diabetes initiatives gaining steam on government and stakeholder sides

Cannabis derived terpenes for sale

Canadian Association of Chiefs of Police. Drug Abuse Committee. Annual Report

O vercom ing Banking Obstacles for Marijuana-Related Businesses. Lori Jean Partner, Krieg DeVault LLP

LIQUOR LICENSE CHANGES AND CANNABIS LEGALIZATION: REGIONAL DISTRICT IMPACTS AND CONSIDERATION

MARIJUANA LEGALIZATION. INITIATIVE STATUTE.

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

Cannabis Legalization Proposed Bylaws

Life s brighter under the sun MEDICAL CANNABIS AND GROUP BENEFITS PLAN COVERAGE

DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT

MARIJUANA: EXPLORING THE PUBLIC HEALTH APPROACH

Permitted Cannabis Marketing Activities

FAQ. A. No, Nature s Ultra products are formulated with a CBD isolate, which by definition contains no THC.

Alberta s System for Legalized Cannabis. alberta.ca/cannabis

Transcription:

Health Care Professionals Forum May 19, 2016

Statistics Update

Licensed Producers There are currently 31 licenses for the production of marijuana for medical purposes There are approximately 400 applications to become a Licensed Producer (LP) being reviewed by Health Canada Three new licenses to produce have been issued since our last meeting (WeedMD, Whistler Medical Marijuana Corp., THC Biomed Ltd.) 3

Current Status of the Marijuana for Medical Purposes Regime LPs are required to submit monthly statistics to Health Canada including production, sale, and inventory amounts. LPs do not provide information pertaining to patient data to Health Canada Authorized licensed production totals 27,000 kg/year or 2,250 kg/month 11,700 kg of dried marijuana has been sold under MMPR licenses since 2013 March 2016 numbers demonstrate that there is sufficient supply of dried marijuana to meet current demand: 1,150 kg sold 1,790 kg produced 10,700 kg in inventory Average authorized amount per day is declining. In March 2016 the average amount authorized was 2.7 grams/day 4

Dried Marijuana As of April 2016: Prices range from $1.75/g to $15/g The average price of dried marijuana is $8.22/g There are approximately 300 strains/product offerings available Most strains are higher in THC/low in CBD, with the highest level of THC observed at 31% 5

Cannabis Oil There are currently 9 licenses to sell oil Authorized licensed production of cannabis oil in Canada is up to 5,000 kg/year or 420 kg/month Approximately 600 kg of cannabis oil has been sold under MMPR licenses since December 2015 As of March 31, 2016, there is sufficient supply of cannabis oil to meet current demand: 400 kg sold 600 kg produced 1,400 kg in inventory As of April 2016: Prices range from $0.95/ml to $4.17/ml The average price of cannabis oil is $2.61/ml There are approximately 30 cannabis oil offerings 6

Patient Access As of March 31, 2016, nearly 54,000 patients are registered under the MMPR. This number has been increasing at an average rate of 9% each month. 7

Marijuana for Medical Purposes Authorization: December Snap Shot December 2015 Average amount of marijuana authorized: 2.9 g/day 68% of medical practitioners supported one patient The average patient to Healthcare practitioner ratio was 5:1 The highest number of patients per doctor was 305 16 physicians authorized more than 100 patients 13 of the 16 are located in Ontario 8

Health Care Practitioners As of January 2016, approximately 6,400 health care practitioners have authorized patient access; under the former MMAR regime (2001-2014) 7,116 physicians supported patient access On average, health care practitioner authorizations increase at a rate of 7% per month Health Canada s summary of peer-reviewed evidence in the Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids, 2013 is in the process of being updated Health Canada is developing a Request for Proposals (RFP) to design Continuing Medical Education (CME) on Marijuana for Medical Purposes RFP is scheduled to be launched in summer 2016 9

Adverse Reactions Hanan Abramovici

Adverse Reaction Reporting - Current status Health Canada collecting Adverse Reaction (AR) reports through the Canada Vigilance Program Spontaneous reporting program for suspected adverse reactions Collects mandatory reports from industry; voluntary reports from HCP and consumers The total number of ARs for a health product cannot be estimated, nor can the numbers of ARs for one health product be compared with those of another, because the number of people using a health product is not known, and not all ARs are reported Caution around data interpretation and causality Monthly line-listings for AR reports sent from Marketed Health Products Directorate (MHPD) to Office of Medical Cannabis (OMC) OMC reviews AR report Compares info in report to Health Canada s cannabis monograph, literature OMC takes action as required 11

Update January 01 2014 April 27 2016 129 Adverse Event Reports (AERs) (serious + non-serious) 105 serious reports 24 non-serious reports 449 AE occurrences in total 5 deaths (from non-medical use) Likely not related to marijuana use only Principally associated with polysubstance abuse (i.e. opioids, depressants) 3 life-threatening 2 unclear if used for medical or non-medical purposes, other false report 12 hospitalizations 10/12 associated with unclear, possible, or confirmed use for medical purposes 94 reports associated with non-medical use 325 AE occurrences 35 reports associated with possible or confirmed use for medical purposes 124 AE occurrences 12

13

14

Current Issues

Updated Daily Amount Fact Sheet In April 2016, the Office of Medical Cannabis released an updated version of the daily Amount Fact Sheet Fact sheet now includes information on cannabis oil, including a section on the Equivalency Factor that the licensed producer must apply to determine the amount of oil is equivalent to one gram of dried marijuana Includes a section on the onset, peak, and duration of effects depending on how the product was administered Includes references to dosing amounts based on recent studies Includes a section on reporting adverse reactions to Health Canada 16

Health Canada s Stakeholder Registry Health Canada wants to know who you are, how to get a hold of you, and what topics you are interested in being consulted on A web-based, centralized information management system for stakeholders and public engagement activities Created to improve the openness and transparency of stakeholder engagement and consultations and allow Canadians to have a stronger say in our departmental/agency priorities and policies Identify the areas in which you want to be consulted, as well as in the level of interaction you wish to have Register online at: http://www.hcsc.gc.ca/ahc-asc/publicconsult/stakeholder-intervenants/indexeng.php 17

Current Issues AG Report on VAC, legalization Auditor General Report on Veterans Affairs Canada On May 3, 2016 the Auditor General released a report on the Department of Veterans Affairs drug benefit program. This report makes a number of recommendations regarding VAC s policy pertaining to reimbursement for marijuana for medical purposes. Impending Legalization The Government of Canada is committed to legalizing, regulating and tightly restricting access to marijuana in order to keep it away from children and to stop criminals from profiting from the illicit trade In the short term, a Task Force will be launched to study every aspect of legalization, and to advise on the design of a new legalized system. Experts, provincial and territorial governments and the public will have an opportunity to provide input. The Government has committed to introducing legislation in Spring 2017 18

Current Issues: New Regulations On March 24, 2016, the Minister of Health confirmed that the Government of Canada would propose changes to the Marihuana for Medical Purposes Regulations (MMPR) to respond to the Federal Court s judgment in Allard v. Canada The Government has until August 24, 2016 to address the limits to reasonable access to marijuana for medical purposes identified by the Federal Court 19